Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences High Content Analysis

Hakim Djaballah's Biography

Hakim Djaballah, CEO, Institute Pasteur - Korea

Dr. Djaballah has several years of industrial experience in early drug discovery gained over the years in pharma and biotech companies. He has extensive experiences in the areas of fluorescence technology, assay development, automation/robotics, HTS, compound & screening data management, software development & novel technologies. Dr Djaballah has been involved in developing and screening several targets in various therapeutic areas, including antibacterials, antivirals, antifungals, diabetes, CNS, cardiovascular, oncology & inflammation. He is currently the director of the high throughput drug screening core facility at Memorial Sloan Kettering Cancer Centre in New York. He obtained his BSc (Hons.) in biochemistry and biotechnology from the University of Birmingham, and his PhD in biochemistry from the University of Leicester, both in England.

Hakim Djaballah Image

A Novel Approach to Overcome Oncogenic Addiction via 3D Model Systems

Thursday, 15 May 2014 at 08:15

Add to Calendar ▼2014-05-15 08:15:002014-05-15 09:15:00Europe/LondonA Novel Approach to Overcome Oncogenic Addiction via 3D Model SystemsHigh Content Analysis in Barcelona, SpainBarcelona,

Classical drug discovery approaches for oncology have relied heavily on killing cancer cells; they have worked very well in some cases but not as good as predicted in others with many failures reported the clinic. We have taken an opportunistic approach looking for small molecules which would selectively revert the addictive state of the cancer cell yielding a vulnerable phenotype. I will describe the approach and discuss our findings thus far with the ultimate goal of progression to the clinic.

Add to Calendar ▼2014-05-14 00:00:002014-05-15 00:00:00Europe/LondonHigh Content AnalysisHigh Content Analysis in Barcelona, SpainBarcelona,